News for Healthier Living

Study Identifies Patients with Obesity Most Likely to Benefit From GLP-1-Based Treatment

Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A Mayo Clinic study offers a potential answer by identifying a distinct biological subtype of obesity that responds especially well to tirzepatide, a medication that mimics two naturally occurring hormones involved in appetite and blood sugar regulation, moving the field closer to precision medicine for obesity.

July 16, 2026


July 16 2026

July 15 2026

July 14 2026

July 13 2026

July 12 2026

July 10 2026

July 9 2026

July 8 2026

July 7 2026

July 6 2026

July 3 2026

July 2 2026